Evergrowth BioHealthcare Capital is investing in the groundbreaking potential of CRISPR/Cas9 technology to revolutionize cancer immunotherapy. By precisely editing the genes of immune cells, CRISPR enables the development of therapies that enhance their ability to target and eliminate cancer cells with unprecedented precision. This targeted approach promises to improve treatment outcomes, reduce side effects, and potentially offer curative options for a wider range of cancers.
Our investment focus includes companies developing CRISPR-engineered T-cell therapies, next-generation CAR-T cells, and novel immuno-oncology approaches. We are also interested in technologies that enhance the safety and efficacy of CRISPR-based therapies, such as improved delivery systems and gene editing tools with enhanced specificity.
Evergrowth is committed to accelerating the development and commercialization of CRISPR-based cancer immunotherapies, with the goal of transforming cancer treatment and improving the lives of patients worldwide.